139 related articles for article (PubMed ID: 19231633)
1. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial.
Rosenson RS; Hislop C; McConnell D; Elliott M; Stasiv Y; Wang N; Waters DD;
Lancet; 2009 Feb; 373(9664):649-58. PubMed ID: 19231633
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease.
Rosenson RS; Elliott M; Stasiv Y; Hislop C;
Eur Heart J; 2011 Apr; 32(8):999-1005. PubMed ID: 21081550
[TBL] [Abstract][Full Text] [Related]
3. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.
Rosenson RS; Hislop C; Elliott M; Stasiv Y; Goulder M; Waters D
J Am Coll Cardiol; 2010 Sep; 56(14):1079-88. PubMed ID: 20863951
[TBL] [Abstract][Full Text] [Related]
4. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial.
Taha AS; McCloskey C; Prasad R; Bezlyak V
Lancet; 2009 Jul; 374(9684):119-25. PubMed ID: 19577798
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
Papp K; Cather JC; Rosoph L; Sofen H; Langley RG; Matheson RT; Hu C; Day RM
Lancet; 2012 Aug; 380(9843):738-46. PubMed ID: 22748702
[TBL] [Abstract][Full Text] [Related]
6. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
[TBL] [Abstract][Full Text] [Related]
7. Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes.
Ryu SK; Mallat Z; Benessiano J; Tedgui A; Olsson AG; Bao W; Schwartz GG; Tsimikas S;
Circulation; 2012 Feb; 125(6):757-66. PubMed ID: 22230483
[TBL] [Abstract][Full Text] [Related]
8. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study.
Tissot AC; Maurer P; Nussberger J; Sabat R; Pfister T; Ignatenko S; Volk HD; Stocker H; Müller P; Jennings GT; Wagner F; Bachmann MF
Lancet; 2008 Mar; 371(9615):821-7. PubMed ID: 18328929
[TBL] [Abstract][Full Text] [Related]
9. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F; Almond S; Margolis D; Brennan C; Min S;
Lancet; 2013 Mar; 381(9868):735-43. PubMed ID: 23306000
[TBL] [Abstract][Full Text] [Related]
10. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial.
Uzun S; Djamin RS; Kluytmans JA; Mulder PG; van't Veer NE; Ermens AA; Pelle AJ; Hoogsteden HC; Aerts JG; van der Eerden MM
Lancet Respir Med; 2014 May; 2(5):361-8. PubMed ID: 24746000
[TBL] [Abstract][Full Text] [Related]
11. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
Raal FJ; Santos RD; Blom DJ; Marais AD; Charng MJ; Cromwell WC; Lachmann RH; Gaudet D; Tan JL; Chasan-Taber S; Tribble DL; Flaim JD; Crooke ST
Lancet; 2010 Mar; 375(9719):998-1006. PubMed ID: 20227758
[TBL] [Abstract][Full Text] [Related]
12. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial.
Tardif JC; McMurray JJ; Klug E; Small R; Schumi J; Choi J; Cooper J; Scott R; Lewis EF; L'Allier PL; Pfeffer MA;
Lancet; 2008 May; 371(9626):1761-8. PubMed ID: 18502300
[TBL] [Abstract][Full Text] [Related]
13. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
[TBL] [Abstract][Full Text] [Related]
14. The sPLA2 Inhibition to Decrease Enzyme Release after Percutaneous Coronary Intervention (SPIDER-PCI) trial.
Džavík V; Lavi S; Thorpe K; Yip PM; Plante S; Ing D; Overgaard CB; Osten MD; Lan J; Robbins K; Miner SE; Horlick EM; Cantor WJ
Circulation; 2010 Dec; 122(23):2411-8. PubMed ID: 21098449
[TBL] [Abstract][Full Text] [Related]
15. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial.
Watz H; Barnacle H; Hartley BF; Chan R
Lancet Respir Med; 2014 Jan; 2(1):63-72. PubMed ID: 24461903
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
Burmester GR; Blanco R; Charles-Schoeman C; Wollenhaupt J; Zerbini C; Benda B; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Soma K; Bradley J; Mebus C;
Lancet; 2013 Feb; 381(9865):451-60. PubMed ID: 23294500
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
[TBL] [Abstract][Full Text] [Related]
19. Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial.
Goudie AR; Lipworth BJ; Hopkinson PJ; Wei L; Struthers AD
Lancet Respir Med; 2014 Apr; 2(4):293-300. PubMed ID: 24717626
[TBL] [Abstract][Full Text] [Related]
20. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.
Burant CF; Viswanathan P; Marcinak J; Cao C; Vakilynejad M; Xie B; Leifke E
Lancet; 2012 Apr; 379(9824):1403-11. PubMed ID: 22374408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
